STOCK TITAN

Roze AI (RZAI) 424B Filings

RZAI NASDAQ

Here are the 424B prospectus supplements from Roze AI Inc. (RZAI) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 424B covers the supplement that carries the terms of a priced offering, so if you follow RZAI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RZAI filings page.

Rhea-AI Summary

Roze AI Inc. (RZAI) registers 18,138,565 common shares for resale by shareholders in connection with its planned direct listing. The registration includes 13,878,565 outstanding shares and 4,260,000 shares issuable upon warrant exercise; Roze AI will receive no proceeds from shareholder resales. The shares are approved for the Nasdaq Capital Market, with trading expected on or about September 29, 2026.

A separate private placement closed September 28, 2026: Roze AI sold 1,250,000 Class C preferred shares at $8.00 each for $10 million in gross proceeds. The conversion price is the lower of $8.00 or 80% of the lowest closing sale price during the five consecutive trading days immediately preceding conversion, subject to a floor initially set at $4.00 that will be $1.00 no later than 120 days after initial issuance.

Controlling shareholder Young Jin Cho holds 58% of voting power and will hold 61% following the listing, placement and issuance of 7,250,000 additional common shares under his consulting agreement. Revenue was $2,295,237 in 2025 versus $8,225,475 in 2024; net loss was $6,030,257 versus $1,444,257. Roze AI reports that its auditor expressed substantial doubt about its ability to continue as a going concern.